Fulgent Genetics, Inc. FLGT Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

RevvityRVTY

——

Mesa LaboratoriesMLAB

——

IlluminaILMN

——

CareDxCDNA

——

Other financials

Income statement

See full

Revenue$71.1M-3.2%

Gross profit$21.5M-24.2%

Operating income-$34.6M-74.9%

Net income-$24.8M-115%

EPS (diluted)-$0.80-116%

Balance sheet

See full

Cash & equivalents$23.4M-65.2%

Total debt$8.2M+40.5%

Total equity$1.0B-6.9%

Total assets$1.2B-4.1%

Cash flow

See full

Operating cash flow$7.1M+260%

CapEx$5.2M+10.3%

Free cash flow$1.9M+121%

Valuation

See full

Market cap$552.11M-7.1%

Enterprise value$536.92M+0.7%

P/S1.7×-0.3×

Profitability

See full

Gross margin38.7%-0.1pp

Operating margin-33.1%+17.4pp

Net margin-23%+43.3pp

FCF margin-36.9%—

Returns & leverage

See full

Return on equity-6.8%+48.2pp

Debt / equity0×0.0×

Current ratio5.3×-1.0×

Where this comes from

Reported directly by Fulgent Genetics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Fulgent Genetics, Inc.'s increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Fulgent Genetics, Inc.'s increase (decrease) in accounts receivable?: Fulgent Genetics, Inc. (FLGT) reported increase (decrease) in accounts receivable of -$16.43M in Q1 2026.
How has Fulgent Genetics, Inc.'s increase (decrease) in accounts receivable changed year-over-year?: Fulgent Genetics, Inc.'s increase (decrease) in accounts receivable decreased by 463.2% year-over-year, from $4.52M to -$16.43M.